Group 1 - BGM Group Ltd. has signed a definitive agreement to acquire 100% of Wonder Dragon Global Limited for a total transaction valuation of RMB550 million by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, expected to be completed in Q2 2025 [1] - Wonder Dragon holds over 3,000 metric tons of premium Qingzhuan dark tea inventory, which includes 1,670 metric tons of raw materials and 1,350 metric tons of finished products, providing a strong foundation for BGM Group's R&D efforts [2] - The acquisition will enhance BGM Group's position in the healthcare sector by expanding its health product portfolio and market reach, leveraging AI technology and big data analytics to modernize traditional industries [3] Group 2 - The CEO of BGM Group stated that the combination of Wonder Dragon's tea resources and the company's biotechnology platform will significantly advance the development and distribution of medicinal tea products, including new health-focused offerings [4] - BGM Group focuses on technology fields such as AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals, aiming to integrate these technologies into its operations [4] - In the biopharmaceutical sector, BGM Group produces oxytetracycline API, crude heparin sodium, and licorice preparations, utilizing AI-assisted decision-making to optimize production and supply chain processes [6]